MS CONTIN contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.
Morphine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing MS CONTIN in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.
MS CONTIN Tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
MS CONTIN Tablets are NOT intended for use as a prn analgesic.
MS CONTIN 100 and 200 mg Tablets ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. These tablet strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.
MS CONTIN TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, DISSOLVED, OR CRUSHED. TAKING BROKEN, CHEWED, DISSOLVED, OR CRUSHED MS CONTIN TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.
MS CONTIN SUMMARY
MS CONTIN (morphine sulfate) is an opioid analgesic.
MS CONTIN is a controlled-release oral morphine formulation indicated for the relief of moderate to severe pain. It is intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days.
The MS CONTIN 200 mg tablet strength is a high dose, controlled-release, oral morphine formulation indicated for the relief of pain in opioid-tolerant patients only.
Media Articles Related to MS Contin (Morphine)
Naloxegol being tested to counteract constipation caused by opioid painkillers
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2014.07.20]
Opioids - strong morphine-based painkillers - are widely prescribed to patients experiencing chronic severe pain.
Shrinking oral cancers with anti-pain agent spares healthy tissues
Source: Cancer / Oncology News From Medical News Today [2014.07.25]
Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School...
Severe pain during and post delivery linked to postpartum depression
Source: Depression News From Medical News Today [2014.07.25]
Controlling pain during childbirth and post delivery may reduce the risk of postpartum depression, writes Katherine Wisner, M.D.
Research led by Temple's Chair of dermatology shows that pain and itch may be signs of skin cancer
Source: Medical Devices / Diagnostics News From Medical News Today [2014.07.25]
Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman...
FDA Approves Hard-to-Abuse Narcotic Painkiller
Source: MedicineNet Chronic Pain Specialty [2014.07.25]
Title: FDA Approves Hard-to-Abuse Narcotic Painkiller
Category: Health News
Created: 7/24/2014 12:36:00 PM
Last Editorial Review: 7/25/2014 12:00:00 AM
Published Studies Related to MS Contin (Morphine)
Periarticular infiltration of 0.25% bupivacaine on top of femoral nerve block and
intrathecal morphine improves quality of pain control after total knee
arthroplasty: a randomized double-blind placebo controlled clinical trial. 
CONCLUSION: Adding periarticular infiltration to femoral block and intrathecal
Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a
double-blinded, randomized, placebo-controlled trial of sustained-release
morphine for treatment of chronic nonradicular low-back pain. 
Although often successful in acute settings, long-term use of opioid pain
medications may be accompanied by waning levels of analgesic response not readily
attributable to advancing underlying disease, necessitating dose escalation to
attain pain relief... Improvements in pain and functional ability were observed.
Tolerability and efficacy of two synergistic ratios of oral morphine and
oxycodone combinations versus morphine in patients with chronic noncancer pain. 
SETTING: Clinical study centers in Australia... CONCLUSION: A 3:2 or 1:2 fixed ratio combination of morphine and oxycodone (MOX)
Long-acting morphine following hip or knee replacement: a randomized,
double-blind and placebo-controlled trial. 
routine postoperative regimen for total hip or knee replacement surgery... CONCLUSIONS: Thirty milligrams twice per day of long-acting morphine from days 1
The effect of intravenous morphine on the level of spinal anesthesia with
CONCLUSION: Although some studies had proved the efficacy of systemic use of
Clinical Trials Related to MS Contin (Morphine)
Efficacy and Safety of Intranasal Morphine for Pain After Third Molar Extraction [Completed]
This study involves approximately 200 patients designed to evaluate the efficacy and safety
of intranasal (IN) morphine 7. 5 mg and 15 mg, intravenous morphine (IV) 7. 5 mg, immediate
release oral (PO) morphine 60 mg or placebo in patients with acute postsurgical pain
following third molar extraction.
Intrathecal Morphine in Knee Arthroplasty [Completed]
This study is designed to explore the efficacy lower doses of intra-spinal morphine for pain
relief and side effect profiles of same in the setting of Total Knee Replacement. We
hypothesized that a dose greater than that used in Total Hip Replacement was needed and
wished to find a dose which was effective but had a low side effect profile.
Efficacy and Safety of Intranasal Morphine for Pain After Bunion Surgery [Completed]
Study designed to evaluate the efficacy and safety of Intranasal (IN) Morphine Nasal Spray
(MNS075) 3. 75 mg, 7. 5 mg, 15 mg, and 30 mg, intravenous (IV) morphine 7. 5 mg, or IN placebo
in patients with moderate to severe post-surgical pain following orthopedic surgery. After
initial dosing, up to six (6) doses of IN MNS075 7. 5 mg or 15 mg for up to twenty-four (24)
hours will be evaluated. The rescue dose remained the same for each.
A Study of Kadian NT in Subjects With Pain Due to Osteoarthritis of the Hip or Knee [Completed]
The purpose of this study is to evaluate the efficacy of Kadian NT compared with placebo for
treating moderate to severe chronic pain over a 12 week period.
INFUSE Morphine Study [Completed]
Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine
administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX)
and intravenously conducted in patients in a hospice care setting or through a palliative
care medicine setting. In this within-patient controlled study, each eligible study patient
receives a single injection by each of the three methods of morphine administration,
sequentially on three consecutive days, according to the order specified by a randomization
Each of the three injections consists of 5 mg of morphine (1. 0 mL of 5 mg/mL solution). The
HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be
blinded, the two SC injections will be double-blinded, using the same volume of normal saline
(0. 9% sodium chloride) placebo (1. 0 mL) as HYLENEX.
Reports of Suspected MS Contin (Morphine) Side Effects
Confusional State (15),
Weight Decreased (12),
Drug Ineffective (12),
Renal Failure Acute (12),
Drug Abuse (11), more >>
Page last updated: 2014-07-25